[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"8938bf1a-b3df-4fc1-a9f9-c9727dc17f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT06843629","created_at":"2025-02-27T07:06:33.229Z","updated_at":"2025-02-27T07:06:33.229Z","phase":"","brief_title":"Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors","source_id_and_acronym":"NCT06843629","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-25"},{"id":"a744dd9f-e4be-4b72-a2de-da79e8056978","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800964","created_at":"2023-04-06T14:03:12.774Z","updated_at":"2025-02-25T13:55:05.180Z","phase":"Phase 1","brief_title":"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05800964","lead_sponsor":"Amgen","biomarkers":" MSLN • CDH3","pipe":"","alterations":" ","tags":["MSLN • CDH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 305"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 06/10/2027","primary_completion_date":" 06/10/2027","study_txt":" Completion: 02/12/2028","study_completion_date":" 02/12/2028","last_update_posted":"2025-02-20"},{"id":"2b60e541-1e3c-4090-9044-9dd28f2e4baf","acronym":"A092001","url":"https://clinicaltrials.gov/study/NCT05001880","created_at":"2023-11-29T23:15:50.240Z","updated_at":"2025-02-25T14:16:16.072Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","source_id_and_acronym":"NCT05001880 - A092001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 08/20/2025","primary_completion_date":" 08/20/2025","study_txt":" Completion: 08/20/2025","study_completion_date":" 08/20/2025","last_update_posted":"2025-02-17"},{"id":"5037edde-68fc-4ba2-be19-0dd9cdd215d1","acronym":"INFINITE","url":"https://clinicaltrials.gov/study/NCT03710876","created_at":"2025-02-26T07:43:54.912Z","updated_at":"2025-02-26T07:43:54.912Z","phase":"Phase 3","brief_title":"Efficacy \u0026 Safety of RAd-IFN Administered with Celecoxib \u0026 Gemcitabine in Patients with Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT03710876 - INFINITE","lead_sponsor":"Ferring Ventures Limited","biomarkers":" MSLN • EFEMP1","pipe":"","alterations":" ","tags":["MSLN • EFEMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-11-08"},{"id":"3459cfe0-8df3-41ce-b99a-ba11d3ea3232","acronym":"EVEREST-2","url":"https://clinicaltrials.gov/study/NCT06051695","created_at":"2023-09-25T14:10:18.366Z","updated_at":"2024-07-02T16:34:59.359Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT06051695 - EVEREST-2","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-06-04"},{"id":"67a7cc8f-4495-4593-a5ec-9a4e0b7286d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02414269","created_at":"2021-01-18T11:32:05.371Z","updated_at":"2024-07-02T16:35:02.997Z","phase":"Phase 1/2","brief_title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","source_id_and_acronym":"NCT02414269","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-17"},{"id":"e9f712c9-43ca-4d3b-9a6c-4c80e514d787","acronym":"NCI-2018-01503","url":"https://clinicaltrials.gov/study/NCT03587311","created_at":"2021-01-29T07:17:35.675Z","updated_at":"2024-07-02T16:35:02.670Z","phase":"Phase 2","brief_title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03587311 - NCI-2018-01503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/12/2018","start_date":" 10/12/2018","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2024-05-17"},{"id":"09261b2f-42ac-4b72-856f-4daf46603021","acronym":"NCI10208","url":"https://clinicaltrials.gov/study/NCT03816358","created_at":"2021-01-18T18:51:22.211Z","updated_at":"2024-07-02T16:35:03.288Z","phase":"Phase 1","brief_title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03816358 - NCI10208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-16"},{"id":"1feb857d-51e5-4682-a570-aafec2b08650","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568680","created_at":"2022-10-06T14:56:16.043Z","updated_at":"2024-07-02T16:35:03.301Z","phase":"Phase 1","brief_title":"SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","source_id_and_acronym":"NCT05568680","lead_sponsor":"Verismo Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SynKIR-110"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-05-16"},{"id":"cadff643-56b0-4e97-baf3-eaa0cd1d40bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05693844","created_at":"2023-01-23T16:00:11.670Z","updated_at":"2024-07-02T16:35:04.514Z","phase":"Phase 1/2","brief_title":"Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05693844","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • CD40 ligand expressing MSLN-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-10"},{"id":"430c3067-053f-432e-8dd9-54e297aab048","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577326","created_at":"2021-01-29T07:21:30.020Z","updated_at":"2024-07-02T16:35:06.711Z","phase":"Phase 1","brief_title":"Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma","source_id_and_acronym":"NCT04577326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2025-02-25T14:28:16.858Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"75a6d88a-b107-4182-b4f0-b14a5142fd63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04175847","created_at":"2021-01-29T07:19:59.914Z","updated_at":"2024-07-02T16:35:18.633Z","phase":"Phase 1/2","brief_title":"A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04175847","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 04/14/2020","start_date":" 04/14/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-20"},{"id":"77e12794-7dd2-4ce2-bacc-b40dca21f7bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375825","created_at":"2022-05-17T12:54:06.483Z","updated_at":"2024-07-02T16:35:21.326Z","phase":"Phase 1","brief_title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","source_id_and_acronym":"NCT05375825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2024","start_date":" 02/06/2024","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2024-02-01"},{"id":"3e892831-b0ba-4503-947a-efcabbf14146","acronym":"","url":"https://clinicaltrials.gov/study/NCT05623488","created_at":"2022-11-21T14:57:07.845Z","updated_at":"2024-07-02T16:35:22.341Z","phase":"Phase 1","brief_title":"CAR T Cells in Mesothelin-Expressing Breast Cancer","source_id_and_acronym":"NCT05623488","lead_sponsor":"University of Pennsylvania","biomarkers":" HER-2 • ER • PGR • MSLN","pipe":" | ","alterations":" ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative","tags":["HER-2 • ER • PGR • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER negative • MSLN expression • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2038","study_completion_date":" 02/01/2038","last_update_posted":"2024-01-24"},{"id":"1709c9a1-ac1e-4f56-aabe-efd83c0933f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126630","created_at":"2021-01-18T15:24:22.600Z","updated_at":"2024-07-02T16:35:23.903Z","phase":"Phase 1/2","brief_title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","source_id_and_acronym":"NCT03126630","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression • MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-01-10"},{"id":"bf40d4c1-dcd3-4943-b816-d258ac3bd571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508334","created_at":"2022-08-19T17:10:11.271Z","updated_at":"2024-07-02T16:35:23.981Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05508334","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-10"},{"id":"6c76a251-4026-4ad4-94d6-b2b81e644662","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809766","created_at":"2021-03-22T11:52:20.228Z","updated_at":"2024-07-02T16:35:24.105Z","phase":"Phase 1","brief_title":"Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04809766","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-09"},{"id":"9a153527-03e4-4f0e-a267-102de598735a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410717","created_at":"2022-06-08T11:58:15.716Z","updated_at":"2024-07-02T16:35:24.094Z","phase":"Phase 1","brief_title":"CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors","source_id_and_acronym":"NCT05410717","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" AXL • MSLN • CLDN6 • GPC3","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AXL • MSLN • CLDN6 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6-CAR-NK cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 05/31/2034","study_completion_date":" 05/31/2034","last_update_posted":"2024-01-09"},{"id":"3be9f507-67a2-4cb7-a07b-b039d2c87116","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164666","created_at":"2021-12-21T16:53:48.131Z","updated_at":"2024-07-02T16:35:25.177Z","phase":"Phase 1","brief_title":"A Study of TAK-103 in Adult With Solid Tumors","source_id_and_acronym":"NCT05164666","lead_sponsor":"Takeda","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2023-12-27"},{"id":"99889667-7df9-4ba0-9746-9b7586ccaa67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779917","created_at":"2023-03-22T14:03:05.395Z","updated_at":"2024-07-02T16:35:29.095Z","phase":"Phase 1","brief_title":"Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT05779917","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mesothelin/GPC3/GUCY2C-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2033","study_completion_date":" 03/10/2033","last_update_posted":"2023-11-15"}]